Clinical outcomes of ranibizumab combined with vitrectomy in treatment of patients with diabetic retinopathy accompanied by neovascular glaucoma / 眼科新进展

ABSTRACT

Objective To investigate the efficacy of ranibizumab combined with pars plana vitrectomy (PPV) in treatment of patients with diabetic retinopathy together with neovascular glaucoma.Methods A retrospective analysis of 16 patients (16 eyes) with diabetic retinopathy accompanied by neovascular glaucoma underwent vitrectomy combined with ranibizumab between June 2013 and June 2017 was conducted.Data were collected on patients' intraocular pressure (IOP),best-corrected visual acuity (BCVA),iris neovascularization,chamber angle changes before and after surgery,and the postoperative complications were recorded.Results No significant difference was approached in IOP before surgery and 1 day after ranibizumab injection [(42.54 ± 16.52) mmHg vs.(38.78 ± 11.38)mmHg,1 kPa =7.5 mmHg] (P＞0.05).And there was also no significant difference in the IOP before surgery and 1 week after vitrectomy [(45.30 ± 12.20) mmHg vs.(42.54 ± 16.52) mmHg] (P ＞0.05);The IOP at 1 month,3 months and 6 months after surgery was (27.56 ± 19.38) mmHg,(20.49 ± 18.66) mmHg and (19.79 ± 16.53) mmHg,respectively,which were significantly different from preoperative IOP (all P ＜ 0.05).At the end of the follow-up,iris neovascularization completely disappeared in 10 eyes (62.5％) and iris neovascularization was significantly lessened in 6 eyes (37.5％).Conclusion Ranibizumab with PPV for diabetic retinopathy and neovascular glaucoma can effectively reduce intraocular pressure and postoperative complications as well as improve visual acuity slightly.